Chronic Lymphocytic Leukemia: Novel Therapies in the Pipeline

Video

Exciting novel-based treatment strategies being investigated in chronic lymphocytic leukemia.

Susan O’Brien, MD: Just to wrap up, is there any new novel strategy or really exciting data that we haven’t covered? Maybe since you’re very familiar with it, you want to say a word about the noncovalent inhibitors. I know the pirtobrutinib data are being updated this year at ASH [American Society of Hematology annual meeting], and also we’re going to hear data, which we haven’t heard in a long time, on what used to be the ArQule drug and is now the Merck drug. I know you were leading the charge with pirtobrutinib, and maybe we can just close with a few words about I think the excitement we all have for the noncovalent inhibitors.

Anthony Mato, MD, MSCE: Sure. Yes, it’s an exciting class or an exciting potential mechanism of action in 2 drugs that are frontrunners here. The ARQ 531 molecule, which I think is now called nemtabrutinib, that’s the new name for it. Then pirtobrutinib, which was formerly LOXO-305. Interesting molecules in that they really are targeting relapsed/refractory CLL [chronic lymphocytic leukemia], particularly in patients who’ve been exposed to a prior BTK [Bruton tyrosine kinase] inhibitor and have developed the most common mechanism of resistance, which is a cysteine 481 mutation. They have a different binding mode. They bind to a different location on BTK, and the clinical data really support the fact that these drugs are active in an unmet need patient population. In terms of the LOXO-305 [pirtobrutinib] data, which I’m more familiar with, it turns out it’s a really clean BTK inhibitor in terms of its AE [adverse event] profile, a discontinuation rate of about 1% due to adverse events, which is wonderful, but not many of the classic BTK inhibitor-associated toxicities.

It’s early days, but it’s nice to have molecules that address an unmet need that happen to be well tolerated, which from a sequencing perspective can continue remissions long term for patients. The other class, which we don’t have to go over the data because there’s not a whole lot yet, is the bispecific antibodies. They seem to be really interesting and exciting, and there are some data to be presented at the ASH meeting, at least there’s a poster presentation on one of these molecules. Those are 2 really interesting classes and many other targets that are in development as well.

Susan O’Brien, MD: It’s exciting times. Well, it’s been exciting times for a while now, but it continues to be.

Anthony Mato, MD, MSCE: Yes.

Susan O’Brien, MD: Thank you, Anthony, for this really interesting conversation, and thank you, the audience. We hope you found this program informative.

Anthony Mato, MD, MSCE: Thank you so much.

Transcript edited for clarity.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Related Content